Sermorelin Tablets: Do Pills or Sublingual Forms Have Any Evidence?
Sermorelin is sold online as a pill or dissolving tablet. The published research is about injections.
Words by the editors ·
Sponsored
No sermorelin tablet has an FDA label, and we found no published trial of one in people. A DailyMed search on October 28, 2026 listed no sermorelin product at all.1 The tablets and dissolving "sublingual" forms sold online are compounded, which means the FDA does not verify their safety, effectiveness or quality before they are marketed.2 The published human work on sermorelin and its close relatives used injections, and the one non-injected route that was tested, the nose, absorbed little.75
In brief
- A DailyMed search on October 28, 2026 listed no sermorelin product, and the FDA does not verify compounded drugs for safety, effectiveness or quality.12
- We found no published human study of a sermorelin tablet or sublingual dose.
- Reviews of oral peptide drugs name enzymatic breakdown, low permeability and weak absorption as the barriers.34
- A nasal GHRH(1-29)-NH2 spray had 3 to 5% bioavailability in 30 healthy men, and in children the response faded within weeks.56
Is there a sermorelin tablet that has been tested?
We did not find one. Searches of PubMed on October 28, 2026 for sermorelin together with oral, sublingual or nasal administration returned no study of a sermorelin tablet or sublingual dose. The only trials of a non-injected route we found used a nasal spray of a related peptide, and they are decades old. That is a gap in the evidence, not proof that a tablet cannot be made to work, but it means any claim about a tablet's effect is untested.
Why is a peptide hard to give as a tablet?
Sermorelin is a 29 amino acid analogue of growth hormone-releasing hormone (GHRH).7 Reviews of oral peptide drugs describe the same obstacle for peptides of this kind: the gastrointestinal tract breaks them down with enzymes, and their low permeability gives weak absorption.3 A 2024 review of oral bioactive peptides likewise names limited oral bioavailability, gastrointestinal stability and poor transport across the gut lining as the main barriers.4 The 2023 review adds that most work on oral protein delivery rests on in vitro and animal data, and that safety and limits in humans remain uncertain.3
Sublingual and dissolving formats aim to skip the stomach by absorbing through the mouth lining. We found no human data showing that this works for sermorelin, and the barriers named for oral peptides, low permeability among them, are not removed by changing the dosage form on its own.
What happened when a related peptide was given through the nose?
The nearest test of a non-injected route is a pair of 1993 studies of GHRH(1-29)-NH2, a 29 amino acid GHRH analogue. Its abstracts do not use the name sermorelin, so treat the match as close, not certain.
| Study | Who and what | What it found |
|---|---|---|
| Wilton 19935 | 30 healthy men aged 19 to 43; intravenous or intranasal dosing | Absorption through the nasal mucosa was low, with bioavailability of only 3 to 5%. The intranasal dose that gave a maximal response was about 50 micrograms/kg, roughly as potent as 1 microgram/kg given intravenously |
| Hümmelink 19936 | 8 short prepubertal children with growth hormone deficiency; 50 micrograms/kg nasal, three times a day for 6 months | Peak responses fell over time, antibodies to the peptide appeared in three children after 6 weeks, height velocity did not increase at 6 months, and two stopped treatment. The authors concluded the nasal form was not suitable in its present form |
Both are small, old, and made with a product formulation that is not on the market, so the figures do not predict what a modern tablet would do. What they show is the size of the problem: even through the thinner nasal membrane, about 50 times the intravenous dose per kilogram was needed for a comparable response.5
What is the evidence for the injected form?
Injection is where the human data are. A review of sermorelin in children with growth hormone deficiency describes intravenous 1 microgram/kg as a rapid test for growth hormone deficiency, and says limited data show once daily subcutaneous 30 micrograms/kg at bedtime was effective in treating some prepubertal children.7 In adults, our own sermorelin dosage article covers the one retrospective series we found: 14 of 105 men had IGF-1 measured, and it rose from 159.5 to 239.0 on 100 mcg of sermorelin combined with other secretagogues.8 That study does not isolate sermorelin, and it did not test a tablet.
Adverse events in the pediatric review were transient facial flushing and pain at the injection site.7 Our sermorelin side effects page lays out the rest.
None of this means injection carries no risk or is established for every use. It means the studies behind sermorelin's reputation tested a route that a tablet does not copy, so the tablet needs its own evidence before anyone can say what dose, if any, would be appropriate.
What should you ask before buying sermorelin tablets?
- Is it a drug product or a supplement? The FDA describes compounded drugs as made for an individual patient, so a seller offering tablets with no prescription and no clinician review is not describing a compounded drug.2
- What does the seller cite? Ask for a human study of that tablet. If the citation is about injections or about a different peptide, it does not apply.
- Who makes it? The FDA says it does not review compounded drugs for safety or effectiveness before they are marketed, so the pharmacy and prescriber are the only checks.2
- What dose is on the label? No approved adult sermorelin label exists to compare it to.1
Sponsored: sermorelin from Vea Health, an injection route
This section is sponsored: we have a financial relationship with Vea Health. It is not a recommendation to use sermorelin, and it does not offer a tablet.
Vea Health says it offers sermorelin injections prescribed by a licensed clinician after an online health questionnaire, filled by a state-licensed U.S. compounding pharmacy, and that you are not charged unless a clinician approves the prescription.9 The page we loaded describes injections, not tablets. Compounded sermorelin is not FDA-approved.2 Tell any prescriber about cancer, pituitary or thyroid conditions, diabetes and every medicine you take.
Bottom line
A sermorelin tablet is an untested product. The published human data are about injections, a nasal spray of a related peptide absorbed 3 to 5% in healthy men, and reviews saying oral peptides face enzyme breakdown and poor absorption.53 Before paying for a tablet, ask the seller for a human study of that exact form, and for background on what sermorelin is and what it has and has not been shown to do, read what is sermorelin.
Questions
Do sermorelin tablets work?
No human study of a sermorelin tablet was found. The published data cover injections, plus old nasal-spray studies of a related peptide that showed 3 to 5% absorption in healthy men.
Is oral sermorelin FDA-approved?
No. A DailyMed search on October 28, 2026 listed no sermorelin product, and compounded drugs are not FDA-approved.
Why can't peptides be taken as pills?
Reviews say the gut breaks peptides down with enzymes and their low permeability leads to weak absorption, so most are injected.
Is sublingual sermorelin better than a swallowed tablet?
No human data we found compare them or test sublingual sermorelin. Dissolving under the tongue avoids the stomach, but absorption of this peptide through the mouth is unproven.
Also in this edition
Part of our guide: Sermorelin: The Complete Guide
Notes
- Sermorelin search. DailyMed, U.S. National Library of Medicine. Searched October 28, 2026.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.
- Peng H, et al. Challenges and opportunities in delivering oral peptides and proteins. Expert Opin Drug Deliv. 2023. PubMed 37450427.
- Wang X, et al. Obstacles, research progress, and prospects of oral delivery of bioactive peptides: a comprehensive review. Front Nutr. 2024. PubMed 39610876.
- Wilton P, et al. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993. PubMed 8329825.
- Hümmelink R, et al. Intranasal administration of growth hormone-releasing hormone(1-29)-NH2 in children with growth hormone deficiency: effects on growth hormone secretion and growth. Acta Paediatr Suppl. 1993. PubMed 8329828.
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999. PubMed 18031173.
- Sigalos JT, et al. Growth hormone secretagogue treatment in hypogonadal men raises serum insulin-like growth factor-1 levels. Am J Mens Health. 2017. PubMed 28830317.
- Vea Health. Sermorelin intake. Accessed October 9, 2026.